Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study to Evaluate the Safety and Tolerability of Multiple-Dose Intravitreal Injections of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration Who Have Completed the Treatment Phase of a Genentech-Sponsored Phase I or Phase I/II rhuFab V2 Study

NCT00095433 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00095433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00095433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study to Evaluate the Safety and Tolerability of Multiple-Dose Intravitreal Injections of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration Who Have Completed the Treatment Phase of a Genentech-Sponsored Phase I or Phase I/II rhuFab V2 Study
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2002
Completion date
August 31, 2006
Enrollment
100
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration